DT Cloud Star Acquisition Corp announced a business combination agreement with biotech firm PrimeGen US, Inc. in early 2026. The company extended the deadline to complete the business combination to March 26, 2026.

• On February 2, 2026, DT Cloud Star Acquisition Corp entered into a Business Combination Agreement with PrimeGen US, Inc., a biotech company, marking a significant step toward completing its initial business combination [S1].
• On March 16, 2026, the company deposited $150,000 into its trust account to extend the deadline for completing the business combination by two months to March 26, 2026 [S1].
• Recent news coverage highlights PrimeGen’s plan to go public through the SPAC deal with DT Cloud Star Acquisition Corp [N1].

The company’s management team has extensive experience in private equity and capital markets, which supports its ability to identify and execute an attractive business combination. The recent agreement to combine with PrimeGen US, Inc., a biotech firm, demonstrates progress in executing its business strategy. The SPAC structure offers target companies an alternative to traditional IPOs, potentially accelerating growth and access to capital. The company’s broad acquisition criteria and flexible deal structuring capabilities may enable it to capitalize on diverse opportunities across industries and geographies.

DT Cloud Star Acquisition Corp has no operating history or revenues and depends entirely on completing a business combination to generate value. The company’s financial position shows limited cash and a low current ratio, which may constrain operational flexibility. The SPAC faces intense competition from other blank check companies and investment firms with greater resources. Completion of the business combination is subject to various conditions, including shareholder approval, and there is no assurance the transaction will be consummated. The company’s focus on a biotech target may expose it to sector-specific risks and regulatory challenges.

As a blank check company, DT Cloud Star Acquisition Corp’s competitive strengths lie in its experienced management team with a proven track record in private equity and capital markets, its broad and deep relationship network for sourcing acquisition opportunities, and its ability to structure complex transactions. The company’s public listing status offers an alternative to traditional IPOs for target businesses, potentially providing a faster, less costly route to public markets with greater certainty of execution. These factors may provide a competitive advantage in identifying and completing a business combination, although the company faces competition from other SPACs and investment entities with greater resources.

• Dependence on Completing a Business Combination: The company has no operations or revenues and depends on successfully identifying and consummating a business combination to create shareholder value. Failure to complete a transaction may result in liquidation and loss of investment.
• Financial Constraints: As of December 31, 2025, the company had limited cash and a low current ratio, which may limit its ability to operate or pursue opportunities without additional financing.
• Competition for Targets: The company competes with other SPACs, private equity firms, and investment entities that may have greater financial and operational resources, potentially limiting its ability to secure attractive business combinations.
• Regulatory and Market Risks: The business combination and subsequent operations may be subject to regulatory approvals, market conditions, and shareholder votes, any of which could delay or prevent consummation of the transaction.
• Sector-Specific Risks: The announced target, PrimeGen US, Inc., operates in the biotech sector, which may involve regulatory, clinical, and market risks inherent to the industry.